Prana moves forward on Alzheimer's treatment
Friday, 05 April, 2002
A treatment for Alzheimer's Disease is one step closer after the successful completion of a Phase II clinical trial by Prana Biotechnology for its drug PBT-1 (Iodochlorhydroxyquin).
The trial was performed on 32 patients. Half of the patients received the drug and half received a placebo, in a randomised double blind study. Full analysis of the results has not been completed.
Earlier studies in transgenic animals were published last year in the journal Neuron.
Prana's Executive Chairman, Geoffrey Kempler, said that as the current study was being prepared for publication, the company could not comment further on the results at this point in time.
Kempler said the company was pleased with the results, "It has given us a vote of confidence to keep moving forward."
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
